Saturday 17 October 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 77.1% and free cash flow fell 201.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
69.27
2.53
−3.52%
Follow MNPR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
56.10 | 51.35 | 56.05 | 33.56 |
Net Debt/EBITDA |
35.10 | 22.81 | 22.82 | 18.27 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.61 | 0.65 | 0.89 | 0.61 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.29) | (0.45) | (0.41) | (0.38) | |
Cash per Share |
20.17 | 18.94 | 16.11 | 15.72 | |
Shareholders Equity per Share |
19.87 | 18.60 | 15.86 | 15.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.87 | 18.60 | 15.86 | 15.32 | |
Free Cash Flow |
(2.09) | (3.37) | (3.47) | (3.25) | |
Working Capital |
141.52 | 137.73 | 135.29 | 130.75 | |
Net Current Asset Value |
141.45 | 137.57 | 135.15 | 130.64 | |
| Other line items | |||||
Quick Ratio |
55.94 | 51.33 | 55.94 | 33.44 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.45) | (0.41) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.85 | 2.49 | 1.97 | 2.80 | |
Average Assets |
75.13 | 100.50 | 96.53 | 94.42 | |
Average Common Equity |
73.25 | 96.43 | 94.49 | 91.53 |
Columns are period end dates